Hasil Pencarian - Hidetoshi Hayashi, MD, PhD

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

    Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report oleh Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study oleh Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN oleh Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study

    Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study oleh Hiroaki Akamatsu, MD, PhD, Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Daichi Fujimoto, MD, Atsushi Hayata, MD, PhD, Koji Haratani, MD, PhD, Yuichi Ozawa, MD, PhD, Takeshi Yoshida, MD, PhD, Tsutomu Iwasa, MD, PhD, Toshio Shimokawa, MD, Keisuke Tomii, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society

    Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society oleh Yuichi Ozawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kouji Yamamoto, PhD, Kentaro Ito, MD, Hirotsugu Kenmotsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Takehito Shukuya, MD, PhD, Daichi Fujimoto, MD, PhD, Shunichi Sugawara, MD, PhD, Seiji Niho, MD, PhD, Yuichiro Ohe, MD, PhD, Hiroaki Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Ichiro Yoshino, MD, PhD, Akihiko Gemma, MD, PhD

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

    The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC oleh Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) oleh Jiyun Lee, MD, Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP, Siqin Zhou, MSc Statistics, Shinkyo Yoon, MD, PhD, Siyang Liu, MD, PhD, Ken Masuda, MD, Hidetoshi Hayashi, MD, PhD, Ullas Batra, MD, DM, Dong-Wan Kim, MD, PhD, Yasushi Goto, MD, PhD, Sze Huey Tan, PhD, Yi-Long Wu, MD, Dae Ho Lee, MD, PhD, Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Myung-Ju Ahn, MD, PhD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL

    Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL oleh Shigehiro Yagishita, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Satoru Miura, MD, PhD, Koji Tamada, MD, PhD, Hiroshi Kagamu, MD, PhD, Akinobu Hamada, PhD, Mayu Ohuchi, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Satoshi Hara, MD, Takashi Kijima, MD, PhD, Fujita Masaki, MD, PhD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Masahiro Tatsuno, MSc, Tetsuya Mitsudomi, MD, PhD

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

    A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan oleh Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy

    Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resec... oleh Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)

    Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observationa... oleh Satoru Miura, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Yasushi Goto, MD, PhD, Hidetoshi Hayashi, MD, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Osamu Hataji, MD, PhD, Kohei Fujita, MD, PhD, Masahiro Seike, MD, PhD, Noriko Yanagitani, MD, PhD, Kazumi Nishino, MD, PhD, Satoshi Hara, MD, Ryota Saito, MD, PhD, Masahide Mori, MD, PhD, Takeshi Tsuda, MD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Tetsuya Mitsudomi, MD, PhD

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC oleh Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: